Millions of people receive affordable, high-quality generic medications from the Indian pharmaceutical industry, which is crucial to the global healthcare system. However, despite its achievements, the sector grapples with significant barriers to equitable access to medicines. This study explores the relationship between India’s pharmaceutical sector and accessibility to medicine, highlighting key factors behind the country’s emergence as a leading pharmaceutical hub. The analysis identifies economic constraints, patent regulations, regulatory hurdles, and disparities in healthcare infrastructure as major obstacles to widespread access to medicines. To overcome these issues, the study advocates a comprehensive strategy that includes effective price controls, reforms in intellectual property laws, simplification of regulatory processes, and increased investments in healthcare infrastructure. Additionally, promoting generic medicine adoption, strengthening the pharmaceutical supply chain, and community engagement are essential for improving access to medicines. By adopting a comprehensive and systemic perspective, India can ensure that the benefits of the pharmaceutical industry translate into improved healthcare outcomes for all. The findings underline the importance of collaboration among policymakers, healthcare professionals, and the pharmaceutical industry to enhance accessibility to essential medicines, ultimately contributing to a healthier and more robust society.
Princy Joseph (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: